AbbVie spent billions of dollars to acquire a potential cancer drug known as Rova-T, but the drug is looking more and more like a bad investment, Business Insider reports.
Details: AbbVie has stopped enrolling new patients in a Phase 3 clinical trial for Rova-T, which an outside monitoring committee had recommended. The drug was intended to treat advanced lung cancer. But in the clinical trial, patients taking Rova-T were dying sooner than patients treated with standard chemotherapy, per BI.
Illustration: Sarah Grillo/Axios
Illustration: Eniola Odetunde/Axios
In her first week on the job, Amy Coney Barrett may be deciding which votes to count in the presidential election. By her third week, she’ll be deciding the fate of the Affordable Care Act.
Where it stands: The Senate votes on Barrett’s nomination tomorrow. If she’s confirmed, Chief Justice John Roberts is expected to swear her in at the Supreme Court within hours, an administration official tells Axios.
Photo: Ron Jenkins/Getty Images
The Biden campaign is rebuffing persistent pleas from Texas Democrats to spend at least $10 million in the Lone Star state, several people familiar with the talks tell Axios.
Why it matters: If Texas — which has 38 electoral votes and is steadily getting more blue, but hasn't backed a Democrat for president since 1976 — flipped to the Biden column, it would be game over. But the RealClearPolitics polling average stubbornly hovers at +2.6 for Trump — and Team Biden appears more focused on closer targets.